Bain Capital Life Sciences Investors, LLC Adagio Therapeutics, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $333 Million
- Q2 2025
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 1,799,595 shares of ADGI stock, worth $5.96 Million. This represents 1.79% of its overall portfolio holdings.
Number of Shares
1,799,595
Previous 1,799,595
-0.0%
Holding current value
$5.96 Million
Previous $5.96 Million
-0.0%
% of portfolio
1.79%
Previous 2.0%
Shares
3 transactions
Others Institutions Holding ADGI
# of Institutions
68Shares Held
63.2MCall Options Held
13.9KPut Options Held
0-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million27.49% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx10.2MShares$33.9 Million0.58% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million39.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8.59MShares$28.4 Million1.01% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...